• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Konstantinov Konstantin converted options into 8,400 shares and sold $3,718 worth of shares (2,699 units at $1.38), increasing direct ownership by 329% to 7,432 units to cover taxes

    2/21/23 4:32:01 PM ET
    $CDAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDAK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Konstantinov Konstantin

    (Last) (First) (Middle)
    C/O CODIAK BIOSCIENCES, INC.
    35 CAMBRIDGEPARK DRIVE, SUITE 500

    (Street)
    CAMBRIDGE MA 02140

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Codiak BioSciences, Inc. [ CDAK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Technology Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/16/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/16/2022 M 4,200 A (1) 5,931 D
    Common Stock 08/17/2022 S(2) 1,308 D $2.2129 4,623 D
    Common Stock 02/16/2023 M 4,200 A (1) 8,823 D
    Common Stock 02/17/2023 S(2) 1,391 D $0.5922 7,432 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (3) 08/16/2022 M 4,200 (4) (4) Common Stock 4,200 $0.00 12,600 D
    Restricted Stock Units (3) 02/16/2023 M 4,200 (4) (4) Common Stock 4,200 $0.00 8,400 D
    Explanation of Responses:
    1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
    2. The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
    3. Each RSU represents a contingent right to receive one share of common stock.
    4. On February 16, 2022, the reporting person was granted 16,800 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.
    Remarks:
    /s/ Yalonda Howze, Attorney-in-Fact for Konstantin Konstantinov 02/21/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDAK

    DatePrice TargetRatingAnalyst
    2/22/2022$34.00 → $24.00Outperform
    Wedbush
    2/11/2022$19.00Buy
    Goldman Sachs
    More analyst ratings

    $CDAK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Codiak BioSciences Inc.

      25-NSE - Codiak BioSciences, Inc. (0001659352) (Subject)

      5/2/23 1:35:25 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form NT 10-K filed by Codiak BioSciences Inc.

      NT 10-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/28/23 7:34:56 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/27/23 9:59:55 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush reiterated coverage on Codiak BioSciences with a new price target

      Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously

      2/22/22 8:48:06 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Goldman Sachs initiated coverage on Codiak BioSciences with a new price target

      Goldman Sachs initiated coverage of Codiak BioSciences with a rating of Buy and set a new price target of $19.00

      2/11/22 6:11:40 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care